TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group.

Chiara Cremolini, Federica Marmorino, Fotios Loupakis, Gianluca Masi, Carlotta Antoniotti, Lisa Salvatore, Marta Schirripa, Luca Boni, Vittorina Zagonel, Sara Lonardi, Giuseppe Aprile, Emiliano Tamburini, Vincenzo Ricci, Monica Ronzoni, Filippo Pietrantonio, Chiara Valsuani, Gianluca Tomasello, Alessandro Passardi, Giacomo Allegrini, Samantha Di DonatoDaniele Santini, Alfredo Falcone, all the investigators of the Gruppo Oncologico del Nord Ovest

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

BACKGROUND: Chemotherapy plus bevacizumab is a standard first-line treatment for unresectable metastatic colorectal cancer patients. Different chemotherapy backbones may be chosen, including one to three drugs, based on patients' general conditions and comorbidities, treatments' objectives, and disease characteristics. TRIBE trial demonstrated a significant advantage in terms of progression-free survival and overall survival for FOLFOXIRI plus bevacizumab as compared with FOLFIRI plus bevacizumab. Based on recent evidence, the de-intensification of the upfront regimen after 4-6 months of treatment is nowadays regarded as a valuable option. Moreover, the prolonged inhibition of angiogenesis, and in particular the continuation of bevacizumab beyond the evidence of disease progression, is an efficacious strategy in the treatment of metastatic colorectal cancer patients.METHODS/DESIGN: TRIBE-2 is a prospective, open-label, multicentric phase III randomized trial in which unresectable and previously untreated metastatic colorectal cancer patients are randomized to receive first-line FOLFOX plus bevacizumab followed by FOLFIRI plus bevacizumab after disease progression or FOLFOXIRI plus bevacizumab followed by the re-introduction of the same regimen after disease progression. The primary endpoint is to compare the efficacy of the two proposed treatment strategies in terms of Progression Free Survival 2.DISCUSSION: The TRIBE-2 study aims at answering the question whether the upfront use of FOLFOXIRI improves the clinical outcome of metastatic colorectal cancer patients, when compared with the pre-planned, sequential use of oxaliplatin-based and irinotecan-based doublets. Both proposed treatment strategies are designed to exploit the effectiveness of the prolonged inhibition of angiogenesis, alternating short (up to 4 months) induction periods and less intensive maintenance phases.TRIAL REGISTRATION: TRIBE2 is registered at Clinicaltrials.gov: NCT02339116 . January 12, 2015. TRIBE-2 is registered at EUDRACT 2014-004436-19, October 10, 2014.
Original languageEnglish
JournalBMC Cancer
Volume17
Issue number1
DOIs
Publication statusPublished - Jun 9 2017

Fingerprint

Colorectal Neoplasms
Disease Progression
oxaliplatin
irinotecan
Disease-Free Survival
Therapeutics
Drug Therapy
Bevacizumab
Comorbidity
Maintenance
Survival
Pharmaceutical Preparations

Keywords

  • Journal Article

Cite this

Cremolini, C., Marmorino, F., Loupakis, F., Masi, G., Antoniotti, C., Salvatore, L., ... Ovest, A. T. I. O. T. G. O. D. N. (2017). TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group. BMC Cancer, 17(1). https://doi.org/10.1186/s12885-017-3360-z

TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group. / Cremolini, Chiara; Marmorino, Federica; Loupakis, Fotios; Masi, Gianluca; Antoniotti, Carlotta; Salvatore, Lisa; Schirripa, Marta; Boni, Luca; Zagonel, Vittorina; Lonardi, Sara; Aprile, Giuseppe; Tamburini, Emiliano; Ricci, Vincenzo; Ronzoni, Monica; Pietrantonio, Filippo; Valsuani, Chiara; Tomasello, Gianluca; Passardi, Alessandro; Allegrini, Giacomo; Di Donato, Samantha; Santini, Daniele; Falcone, Alfredo; Ovest, all the investigators of the Gruppo Oncologico del Nord.

In: BMC Cancer, Vol. 17, No. 1, 09.06.2017.

Research output: Contribution to journalArticle

Cremolini, C, Marmorino, F, Loupakis, F, Masi, G, Antoniotti, C, Salvatore, L, Schirripa, M, Boni, L, Zagonel, V, Lonardi, S, Aprile, G, Tamburini, E, Ricci, V, Ronzoni, M, Pietrantonio, F, Valsuani, C, Tomasello, G, Passardi, A, Allegrini, G, Di Donato, S, Santini, D, Falcone, A & Ovest, ATIOTGODN 2017, 'TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group.', BMC Cancer, vol. 17, no. 1. https://doi.org/10.1186/s12885-017-3360-z
Cremolini, Chiara ; Marmorino, Federica ; Loupakis, Fotios ; Masi, Gianluca ; Antoniotti, Carlotta ; Salvatore, Lisa ; Schirripa, Marta ; Boni, Luca ; Zagonel, Vittorina ; Lonardi, Sara ; Aprile, Giuseppe ; Tamburini, Emiliano ; Ricci, Vincenzo ; Ronzoni, Monica ; Pietrantonio, Filippo ; Valsuani, Chiara ; Tomasello, Gianluca ; Passardi, Alessandro ; Allegrini, Giacomo ; Di Donato, Samantha ; Santini, Daniele ; Falcone, Alfredo ; Ovest, all the investigators of the Gruppo Oncologico del Nord. / TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group. In: BMC Cancer. 2017 ; Vol. 17, No. 1.
@article{ae809791a9cd4f20b247f8a960215599,
title = "TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group.",
abstract = "BACKGROUND: Chemotherapy plus bevacizumab is a standard first-line treatment for unresectable metastatic colorectal cancer patients. Different chemotherapy backbones may be chosen, including one to three drugs, based on patients' general conditions and comorbidities, treatments' objectives, and disease characteristics. TRIBE trial demonstrated a significant advantage in terms of progression-free survival and overall survival for FOLFOXIRI plus bevacizumab as compared with FOLFIRI plus bevacizumab. Based on recent evidence, the de-intensification of the upfront regimen after 4-6 months of treatment is nowadays regarded as a valuable option. Moreover, the prolonged inhibition of angiogenesis, and in particular the continuation of bevacizumab beyond the evidence of disease progression, is an efficacious strategy in the treatment of metastatic colorectal cancer patients.METHODS/DESIGN: TRIBE-2 is a prospective, open-label, multicentric phase III randomized trial in which unresectable and previously untreated metastatic colorectal cancer patients are randomized to receive first-line FOLFOX plus bevacizumab followed by FOLFIRI plus bevacizumab after disease progression or FOLFOXIRI plus bevacizumab followed by the re-introduction of the same regimen after disease progression. The primary endpoint is to compare the efficacy of the two proposed treatment strategies in terms of Progression Free Survival 2.DISCUSSION: The TRIBE-2 study aims at answering the question whether the upfront use of FOLFOXIRI improves the clinical outcome of metastatic colorectal cancer patients, when compared with the pre-planned, sequential use of oxaliplatin-based and irinotecan-based doublets. Both proposed treatment strategies are designed to exploit the effectiveness of the prolonged inhibition of angiogenesis, alternating short (up to 4 months) induction periods and less intensive maintenance phases.TRIAL REGISTRATION: TRIBE2 is registered at Clinicaltrials.gov: NCT02339116 . January 12, 2015. TRIBE-2 is registered at EUDRACT 2014-004436-19, October 10, 2014.",
keywords = "Journal Article",
author = "Chiara Cremolini and Federica Marmorino and Fotios Loupakis and Gianluca Masi and Carlotta Antoniotti and Lisa Salvatore and Marta Schirripa and Luca Boni and Vittorina Zagonel and Sara Lonardi and Giuseppe Aprile and Emiliano Tamburini and Vincenzo Ricci and Monica Ronzoni and Filippo Pietrantonio and Chiara Valsuani and Gianluca Tomasello and Alessandro Passardi and Giacomo Allegrini and {Di Donato}, Samantha and Daniele Santini and Alfredo Falcone and Ovest, {all the investigators of the Gruppo Oncologico del Nord}",
year = "2017",
month = "6",
day = "9",
doi = "10.1186/s12885-017-3360-z",
language = "English",
volume = "17",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group.

AU - Cremolini, Chiara

AU - Marmorino, Federica

AU - Loupakis, Fotios

AU - Masi, Gianluca

AU - Antoniotti, Carlotta

AU - Salvatore, Lisa

AU - Schirripa, Marta

AU - Boni, Luca

AU - Zagonel, Vittorina

AU - Lonardi, Sara

AU - Aprile, Giuseppe

AU - Tamburini, Emiliano

AU - Ricci, Vincenzo

AU - Ronzoni, Monica

AU - Pietrantonio, Filippo

AU - Valsuani, Chiara

AU - Tomasello, Gianluca

AU - Passardi, Alessandro

AU - Allegrini, Giacomo

AU - Di Donato, Samantha

AU - Santini, Daniele

AU - Falcone, Alfredo

AU - Ovest, all the investigators of the Gruppo Oncologico del Nord

PY - 2017/6/9

Y1 - 2017/6/9

N2 - BACKGROUND: Chemotherapy plus bevacizumab is a standard first-line treatment for unresectable metastatic colorectal cancer patients. Different chemotherapy backbones may be chosen, including one to three drugs, based on patients' general conditions and comorbidities, treatments' objectives, and disease characteristics. TRIBE trial demonstrated a significant advantage in terms of progression-free survival and overall survival for FOLFOXIRI plus bevacizumab as compared with FOLFIRI plus bevacizumab. Based on recent evidence, the de-intensification of the upfront regimen after 4-6 months of treatment is nowadays regarded as a valuable option. Moreover, the prolonged inhibition of angiogenesis, and in particular the continuation of bevacizumab beyond the evidence of disease progression, is an efficacious strategy in the treatment of metastatic colorectal cancer patients.METHODS/DESIGN: TRIBE-2 is a prospective, open-label, multicentric phase III randomized trial in which unresectable and previously untreated metastatic colorectal cancer patients are randomized to receive first-line FOLFOX plus bevacizumab followed by FOLFIRI plus bevacizumab after disease progression or FOLFOXIRI plus bevacizumab followed by the re-introduction of the same regimen after disease progression. The primary endpoint is to compare the efficacy of the two proposed treatment strategies in terms of Progression Free Survival 2.DISCUSSION: The TRIBE-2 study aims at answering the question whether the upfront use of FOLFOXIRI improves the clinical outcome of metastatic colorectal cancer patients, when compared with the pre-planned, sequential use of oxaliplatin-based and irinotecan-based doublets. Both proposed treatment strategies are designed to exploit the effectiveness of the prolonged inhibition of angiogenesis, alternating short (up to 4 months) induction periods and less intensive maintenance phases.TRIAL REGISTRATION: TRIBE2 is registered at Clinicaltrials.gov: NCT02339116 . January 12, 2015. TRIBE-2 is registered at EUDRACT 2014-004436-19, October 10, 2014.

AB - BACKGROUND: Chemotherapy plus bevacizumab is a standard first-line treatment for unresectable metastatic colorectal cancer patients. Different chemotherapy backbones may be chosen, including one to three drugs, based on patients' general conditions and comorbidities, treatments' objectives, and disease characteristics. TRIBE trial demonstrated a significant advantage in terms of progression-free survival and overall survival for FOLFOXIRI plus bevacizumab as compared with FOLFIRI plus bevacizumab. Based on recent evidence, the de-intensification of the upfront regimen after 4-6 months of treatment is nowadays regarded as a valuable option. Moreover, the prolonged inhibition of angiogenesis, and in particular the continuation of bevacizumab beyond the evidence of disease progression, is an efficacious strategy in the treatment of metastatic colorectal cancer patients.METHODS/DESIGN: TRIBE-2 is a prospective, open-label, multicentric phase III randomized trial in which unresectable and previously untreated metastatic colorectal cancer patients are randomized to receive first-line FOLFOX plus bevacizumab followed by FOLFIRI plus bevacizumab after disease progression or FOLFOXIRI plus bevacizumab followed by the re-introduction of the same regimen after disease progression. The primary endpoint is to compare the efficacy of the two proposed treatment strategies in terms of Progression Free Survival 2.DISCUSSION: The TRIBE-2 study aims at answering the question whether the upfront use of FOLFOXIRI improves the clinical outcome of metastatic colorectal cancer patients, when compared with the pre-planned, sequential use of oxaliplatin-based and irinotecan-based doublets. Both proposed treatment strategies are designed to exploit the effectiveness of the prolonged inhibition of angiogenesis, alternating short (up to 4 months) induction periods and less intensive maintenance phases.TRIAL REGISTRATION: TRIBE2 is registered at Clinicaltrials.gov: NCT02339116 . January 12, 2015. TRIBE-2 is registered at EUDRACT 2014-004436-19, October 10, 2014.

KW - Journal Article

U2 - 10.1186/s12885-017-3360-z

DO - 10.1186/s12885-017-3360-z

M3 - Article

VL - 17

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

IS - 1

ER -